胸腺肽α_1对恶性肿瘤患者化疗期间免疫功能影响

IMMUNOMODULATORY EFFECTS OF THYMOSIN α_1 IN CANCER PATIENTS DURING CHEMOTHERAPY

目的：观察胸腺肽α1（Tα1）对化疗期间恶性肿瘤患者的免疫功能影响。方法：20例晚期恶性肿瘤患者随机分成A，B两组。A组给予单一化疗；B组在化疗同时给予Tα11．6mg／次，sc，2次／周，连用2个月。两组病例在治疗前后分别用流式细胞仪测定外周血T细胞亚群（CD3，CD4，CD8及CD4／CD8）和NK细胞活性。结果：B组的CD4，CD4／CD8和NK细胞活性治疗后明显高于治疗前，有统计学意义（P＜0．05）。治疗后A，B两组相比，B组的NK细胞活性明显高于A组，有统计学意义（P＜0．05）。结论：Tα1能明显提高肿瘤患者的免疫功能，特别对提高NK细胞活性尤为明显，并且没有发现明显的毒副作用，是一种低毒高效的生物反应调节剂。

TO observe the immunomodulatory effects of thymosin α1 in advanced cancer patients during chemotherapy. METHODS: 20 patients with advanced cancer were randomly and equally divided to receive chemotherapy or chemotherapy in combination with thymosin α1 in a twice weekly dose of 1. 6 mg by subcutaneous injection and the treatment was maintained for 2 months. The peripheral blood T cell levels (CD3, CD4, CD8 and CD4 /CD8 )and natural killer(NK)activity of patients in both group were measured by flow cytometry before and after treatment. RESULTS: After treatment, the blood levels of CD4 and CD4/CD8 and NK cell activity in active group were significantly higher than that of before treatment (P < 0. 05 ). After treatment, the NK cell activity in active group was significantly higher than that of control group (P < 0. 05 ). CONCLUSION: The immunological function of cancer patients is significantly elevated by Tα1 treatment, especially the NK cell activity and no obvious side effects were observed.